Cytek Biosciences Résultats passés
Passé contrôle des critères 0/6
Les bénéfices de Cytek Biosciences ont diminué à un taux annuel moyen de -71.5%, tandis que le secteur Life Sciences a vu ses bénéfices augmenter de en baisse à 3.8% par an. Les revenus ont augmenté de en à un taux moyen de 12% par an.
Informations clés
-71.53%
Taux de croissance des bénéfices
-74.46%
Taux de croissance du BPA
| Life Sciences Croissance de l'industrie | 21.51% |
| Taux de croissance des recettes | 12.04% |
| Rendement des fonds propres | -22.59% |
| Marge nette | -36.25% |
| Dernière mise à jour des bénéfices | 31 Mar 2026 |
Mises à jour récentes des performances passées
Recent updates
Mise à jour du récit • May 04
CTKB: 2026 Outlook And Completed Buyback Will Support Balanced Multi Year Setup
Analysts have revised their price target on Cytek Biosciences slightly, making a modest change that reflects updated assumptions on discount rate, revenue growth, profit margin and future P/E, while keeping the fair value estimate steady at $5.00. What's in the News Cytek Biosciences reported that from October 1, 2025 to December 31, 2025, it repurchased 0 shares for $0 million, and completed a total buyback of 3,292,588 shares, or 2.56%, for $15.3 million under the program announced on December 30, 2024 (Key Developments).
Mise à jour du récit • Apr 20
CTKB: Share Repurchases And 2026 Guidance Will Support Future Upside Potential
Analysts have kept their $6.00 price target for Cytek Biosciences unchanged, with only small tweaks to inputs such as discount rate, profit margin assumptions, and future P/E. These adjustments support the view that the current valuation remains aligned with their updated models.Mise à jour du récit • Apr 06
CTKB: 2026 Guidance And Buyback Will Frame Balanced Multi Year Upside Potential
Narrative Update Analysts have lifted their price target on Cytek Biosciences to $5 from $4, pointing to a clearer multi year framework and several potential growth drivers as key reasons for the change. Analyst Commentary Analysts highlighting the higher US$5 price target frame Cytek Biosciences as a name that could benefit if the broader diagnostic tools group sees improving sentiment and clearer multi year guidance.Mise à jour du récit • Mar 22
CTKB: Sector Recovery And 2026 Guidance Will Support Upside Potential
Analysts have raised the target price on Cytek Biosciences shares to $5 from $4, citing improving sentiment in diagnostic tools and a preference for companies with clearer multi year growth frameworks and several potential upside drivers. Analyst Commentary Bullish Takeaways Bullish analysts view the higher US$5 target as a reflection of improving sentiment across diagnostic tools, which supports a more constructive stance on valuation for Cytek Biosciences.Mise à jour du récit • Mar 08
CTKB: Sector Recovery And 2026 Guidance Are Expected To Drive Upside
Analysts have modestly raised their price target framework on Cytek Biosciences to $6.00, supported by a shift toward higher future P/E assumptions and recent Street research that highlights clearer multi year growth pathways and improving investor sentiment in the diagnostic tools group. Analyst Commentary Recent research points to a more constructive stance on Cytek Biosciences, with price targets nudged higher and a focus on how the company fits into a potential recovery in the diagnostic tools group.Mise à jour du récit • Feb 22
CTKB: 2026 Guidance And Multi Year Framework Will Support Upside Potential
Analysts recently lifted Cytek Biosciences' price target to $5 from $4, pointing to a more supportive sector backdrop, higher revenue growth assumptions, and a slightly higher future P/E multiple. They noted that they are focused on companies with clear multi year frameworks and multiple potential growth drivers.Article d’analyse • Feb 13
Cytek Biosciences, Inc.'s (NASDAQ:CTKB) Share Price Is Still Matching Investor Opinion Despite 27% Slump
The Cytek Biosciences, Inc. ( NASDAQ:CTKB ) share price has fared very poorly over the last month, falling by a...Mise à jour du récit • Feb 08
CTKB: 2026 Guidance Will Underpin Multi Year Upside Framework
Analysts have lifted their price target on Cytek Biosciences to $5 from $4, pointing to improving sentiment around the diagnostic tools group and an interest in companies that offer clear multi year growth frameworks with several potential upside drivers. Analyst Commentary Analysts framing Cytek Biosciences around a US$5 price target are generally pointing to companies in the diagnostic tools group that offer clear multi year plans and several possible levers for upside.
Mise à jour du récit • Jan 24
CTKB: Sector Recovery And 2026 Earnings Framework Will Drive Repricing
Analysts have raised their price target on Cytek Biosciences to $5.00 from $4.00, citing refined assumptions around fair value, discount rates, growth, margins, and future P/E as they reassess the company within a recovering diagnostics tools sector. Analyst Commentary Bullish analysts are framing the move to a US$5.00 price target as part of a broader reset across diagnostic tools names, with Cytek Biosciences seen as one of the names that screens well under updated fair value and discount rate assumptions.Mise à jour du récit • Jan 10
CTKB: 2026 Guidance And European Expansion Will Shape Multi Year Framework
Narrative Update Analysts have lifted their price target on Cytek Biosciences to US$5.00 from US$4.00, citing a clearer multi year growth framework, multiple potential growth drivers, and a view that updated 2026 guidance will be important for how the stock fits into a broader sector recovery. Analyst Commentary Recent research highlights a more defined multi year framework for Cytek Biosciences, with attention on how upcoming 2026 guidance could shape market views on growth and sector positioning.Mise à jour du récit • Dec 17
CTKB: European Expansion Will Drive Future Upside Potential
Analysts have maintained their price target for Cytek Biosciences at $5.75, with only minor model refinements to the discount rate, revenue growth expectations, and profit margin assumptions supporting a steady valuation outlook. What's in the News Reaffirmed full year 2025 revenue guidance of $196 million to $205 million, implying growth of -2% to +2% versus 2024, assuming stable currency exchange rates (company guidance) Completed previously announced share repurchase program, buying back 3,292,588 shares, or 2.56% of shares outstanding, for a total of $15.3 million, with no additional shares repurchased in the July 1 to September 30, 2025 period (company disclosure) Relocated and expanded European headquarters to a larger facility in the Life Sciences District of Amsterdam, adding over 40% more space, a warehouse, and a dedicated customer service and training center to support growth in the EMEA region (company announcement) Brought European warehouse operations in house as part of a strategic push to scale the reagent business, aiming to improve quality control, operational efficiency, and turnaround times for customers (company announcement) Valuation Changes Consensus Analyst Price Target (Fair Value): unchanged at $5.75 per share, indicating no shift in overall valuation outlook.Mise à jour du récit • Dec 03
CTKB: Full Year Outlook And Europe Expansion Will Shape Balanced Future Prospects
Analysts have raised their price target on Cytek Biosciences by approximately 12 percent to about 6 dollars per share, citing slightly stronger expectations for long term revenue growth, improved profit margin potential, and a modestly higher future earnings multiple. What's in the News Reaffirmed full year 2025 revenue guidance of 196 million to 205 million dollars, implying flat to modest growth of minus 2 percent to plus 2 percent versus 2024 (company guidance).Article d’analyse • Nov 22
Revenues Tell The Story For Cytek Biosciences, Inc. (NASDAQ:CTKB) As Its Stock Soars 43%
The Cytek Biosciences, Inc. ( NASDAQ:CTKB ) share price has done very well over the last month, posting an excellent...Seeking Alpha • Nov 20
Cytek Biosciences Is A Speculative Buy On Recurring Revenue Growth
Summary Cytek Biosciences offers a full-spectrum cytometry platform. This means they provide instruments, reagents, services, and cloud software. Their main value proposition is to allow clients to achieve higher-parameter cell analysis than conventional flow systems. Its core product portfolio centers around Aurora, Northern Lights, Aurora CS, and Aurora Evo. Each targets a different price-performance tier. Over time, CTKB should continue growing its reagents and service businesses while creating higher-margin recurring revenue. Ultimately, I think the company's valuation multiples and ample cash runway support a bullish rating. Thus, I rate it a 'Buy' at these levels. Read the full article on Seeking AlphaArticle d’analyse • Aug 15
Cytek Biosciences, Inc. (NASDAQ:CTKB) Stock Catapults 26% Though Its Price And Business Still Lag The Industry
NasdaqGS:CTKB 1 Year Share Price vs Fair Value Explore Cytek Biosciences's Fair Values from the Community and select...Mise à jour du récit • Aug 10
Cloud Software And Flow Cytometry Will Unlock Global Opportunity
The consensus price target for Cytek Biosciences has been notably reduced, primarily due to a significant downward revision in revenue growth forecasts, resulting in a new fair value of $5.00 per share. What's in the News Full-year 2025 revenue guidance narrowed to $196 million–$205 million, representing growth of -2% to +2% over the prior year.Article d’analyse • Jul 28
Is Cytek Biosciences (NASDAQ:CTKB) Using Debt Sensibly?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Nouveau récit • May 31
APAC Markets And Recurring Revenues Will Support Life Sciences
Growth in Asia-Pacific and strong recurring revenues from services and reagents offset weaker performance in the US and Europe, supporting long-term stability.Article d’analyse • May 30
The Market Doesn't Like What It Sees From Cytek Biosciences, Inc.'s (NASDAQ:CTKB) Revenues Yet As Shares Tumble 31%
To the annoyance of some shareholders, Cytek Biosciences, Inc. ( NASDAQ:CTKB ) shares are down a considerable 31% in...Seeking Alpha • Apr 28
Why Cytek Biosciences Should Beat Q1 Earnings Expectations
Summary There are still growth drivers that may positively play out in future quarters, so I'm still optimistic on Cytek Biosciences. Cytek's FY2024 adjusted EBITDA surged 77% YoY, indicating robust profitability potential, supported by effective cost management and a solid balance sheet. Despite a 41% YTD stock decline, Cytek's innovative FSP tech and growing Cytek Cloud user base signal strong future growth prospects. Valuation analysis suggests a 22% upside in CTKB stock, with a price target of $4.6/share, assuming continued margin expansion and positive earnings trajectory. Read the full article on Seeking AlphaArticle d’analyse • Apr 16
Is Cytek Biosciences (NASDAQ:CTKB) Using Too Much Debt?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Article d’analyse • Feb 13
Cytek Biosciences, Inc. (NASDAQ:CTKB) Stock's 28% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Cytek Biosciences, Inc. ( NASDAQ:CTKB ) shares have had a horrible month, losing 28% after a relatively good period...Seeking Alpha • Jan 09
Upgrading Cytek Biosciences Stock On An Upcoming Catalyst
Summary I'm upgrading Cytek Biosciences from "Hold" to "Buy" due to improving financials, expanding installed base, and strong demand for Aurora and Northern Lights systems. Cytek's Q3 FY2024 revenue up 7% YoY, driven by international demand; service revenue surged 25% YoY, boosting recurring revenue streams. The recently announced buyback plan went unnoticed, based on the EPS estimates revisions. I'm also expecting a potential catalyst from the upcoming J.P. Morgan Healthcare Conference, which could further drive CTKB stock price recovery and growth in 2025. Despite risks, CTKB's global expansion, technological advancements, and sound financials position it well for long-term shareholder value creation. Read the full article on Seeking AlphaArticle d’analyse • Dec 16
Is Cytek Biosciences (NASDAQ:CTKB) Weighed On By Its Debt Load?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Article d’analyse • Nov 07
Investors Still Aren't Entirely Convinced By Cytek Biosciences, Inc.'s (NASDAQ:CTKB) Revenues Despite 46% Price Jump
Cytek Biosciences, Inc. ( NASDAQ:CTKB ) shareholders would be excited to see that the share price has had a great...Article d’analyse • Sep 13
Cytek Biosciences, Inc.'s (NASDAQ:CTKB) Shares Not Telling The Full Story
With a median price-to-sales (or "P/S") ratio of close to 3.6x in the Life Sciences industry in the United States, you...Article d’analyse • Aug 09
An Intrinsic Calculation For Cytek Biosciences, Inc. (NASDAQ:CTKB) Suggests It's 49% Undervalued
Key Insights Cytek Biosciences' estimated fair value is US$10.66 based on 2 Stage Free Cash Flow to Equity Current...Article d’analyse • Jul 12
Is Cytek Biosciences (NASDAQ:CTKB) Using Debt Sensibly?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Article d’analyse • Jun 04
Potential Upside For Cytek Biosciences, Inc. (NASDAQ:CTKB) Not Without Risk
It's not a stretch to say that Cytek Biosciences, Inc.'s ( NASDAQ:CTKB ) price-to-sales (or "P/S") ratio of 3.6x right...Seeking Alpha • Mar 20
Cytek Biosciences: Undisputed Next-Gen Flow Cytometry Leader
Summary Cytek Biosciences is a leading cellular analysis instrument maker with a focus on the Aurora flow cytometry platform. Despite a downturn in the healthcare market, Cytek has maintained revenue growth above 15% since IPO. Cytek's technological advantage, broadening ecosystem, and potential in the clinical and biopharma space contribute to the leading financials and positive outlook. Read the full article on Seeking AlphaVentilation des recettes et des dépenses
Ventilation des recettes et des dépenses
Comment Cytek Biosciences gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 31 Mar 26 | 204 | -74 | 113 | 36 |
| 31 Dec 25 | 201 | -67 | 108 | 36 |
| 30 Sep 25 | 197 | -13 | 102 | 37 |
| 30 Jun 25 | 196 | -6 | 98 | 38 |
| 31 Mar 25 | 197 | -11 | 94 | 39 |
| 31 Dec 24 | 200 | -6 | 92 | 39 |
| 30 Sep 24 | 201 | -10 | 94 | 41 |
| 30 Jun 24 | 198 | -18 | 93 | 42 |
| 31 Mar 24 | 201 | -12 | 94 | 44 |
| 31 Dec 23 | 193 | -12 | 93 | 44 |
| 30 Sep 23 | 183 | -14 | 90 | 43 |
| 30 Jun 23 | 176 | -6 | 85 | 41 |
| 31 Mar 23 | 166 | -2 | 77 | 37 |
| 31 Dec 22 | 164 | 3 | 68 | 35 |
| 30 Sep 22 | 155 | -1 | 63 | 32 |
| 30 Jun 22 | 148 | -3 | 59 | 30 |
| 31 Mar 22 | 139 | -2 | 52 | 27 |
| 31 Dec 21 | 128 | 0 | 46 | 24 |
| 30 Sep 21 | 120 | 1 | 37 | 22 |
| 30 Jun 21 | 110 | 2 | 31 | 19 |
| 31 Mar 21 | 99 | 4 | 27 | 16 |
| 31 Dec 20 | 93 | 3 | 24 | 14 |
| 31 Dec 19 | 58 | -17 | 17 | 9 |
Des revenus de qualité: CTKB n'est actuellement pas rentable.
Augmentation de la marge bénéficiaire: CTKB n'est actuellement pas rentable.
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: CTKB n'est pas rentable et les pertes ont augmenté au cours des 5 dernières années à un rythme de 71.5% par an.
Accélération de la croissance: Impossible de comparer la croissance des bénéfices de CTKB au cours de l'année écoulée à sa moyenne sur 5 ans car elle n'est actuellement pas rentable
Bénéfices par rapport au secteur d'activité: CTKB n'est pas rentable, ce qui rend difficile la comparaison de sa croissance des bénéfices de l'année écoulée avec celle du secteur Life Sciences ( 3.8% ).
Rendement des fonds propres
ROE élevé: CTKB a un retour sur capitaux propres négatif ( -22.59% ), car il n'est actuellement pas rentable.
Rendement des actifs
Rendement des capitaux employés
Découvrir des entreprises performantes dans le passé
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/05/21 14:31 |
| Cours de l'action en fin de journée | 2026/05/21 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Cytek Biosciences, Inc. est couverte par 9 analystes. 4 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Kyle Mikson | Canaccord Genuity |
| Matthew Sykes | Goldman Sachs |
| Kallum Titchmarsh | Morgan Stanley |